A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2 - Episode 4

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.

EP. 1: Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer
EP. 2: Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer
EP. 3: Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer
Now Viewing
EP. 4: A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2

Related Content:

A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2Lung Cancer
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
Defining Resectability in Stage III NSCLC: Addressing Key Controversies
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC